Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1308 • ACR Convergence 2023
Certolizumab Pegol Shows Longer Retention Rate in Comparison with Other TNF Inhibitors in Patients with Rheumatoid Arthritis and High Rheumatoid Factor Titers at Baseline. a Multicentre and Retrospective Study
Clementina López Medina¹, Jerusalem Calvo², Maria del Carmen Abalos-Aguilera³, Francisco Cepas⁴, Chamaida Plasencia-Rodríguez⁵, Ana Martinez Feito⁶, Alejandro Balsa⁵, Regina Faré-García⁷, Antonio Juan Mas⁷, Virginia Ruiz-Esquide⁸, Luis Sainz-Comas⁹, César Díaz-Torné⁹, Javier Godoy¹⁰, Isabel Anon Onate¹¹, Natalia Mena Vazquez¹², SARA MANRIQUE¹³, Marina soledad Moreno Garcia¹⁴, Rafaela Ortega Castro¹⁵ and Alejandro Escudero-Contreras¹⁶, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ²Reina Sofia University Hospital, Córdoba, Spain, ³Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁴Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, ⁷Son Llazter University Hospital, Palma, Spain, ⁸Hospital Clinic, Rheumatology, Barcelona, Spain, ⁹Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Jaen University Hospital, Jaen, Spain, ¹¹Hospital Universitario de Jaen, Jaen, Spain, ¹²IBIMA, Málaga, Spain, ¹³Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ¹⁴Hospital Miguel Servet, Zaragoza, Spain, ¹⁵Hospital Reina Sofía, Cordoba, Spain, ¹⁶Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain
Background/Purpose: Rheumatoid Factor (RF) is an antibody against the Fc fragment of IgG that contributes to the Rheumatoid Arthritis (RA) development. RF can bind the…
Abstract Number: 1325 • ACR Convergence 2023
Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis with a Maximum Exposure of 8.3 Years
Kevin Withrop¹, Daniel Aletaha², Roberto F. Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Paul Van Hoek⁶, Pieter-Jan Stiers⁷, Vijay Rajendran⁸, Katrien Van Beneden⁶, Jacques-Eric Gottenberg⁹ and Gerd Burmester¹⁰, ¹Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ⁴University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Clinical Research, Galapagos NV, Mechelen, Belgium, ⁹Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ¹⁰Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is an oral Janus kinase 1 preferential inhibitor, approved for the treatment of moderate to severe active rheumatoid arthritis (RA). In previous…
Abstract Number: 1341 • ACR Convergence 2023
Impact of Ultrasound on Physician Assessments of Patients with RA with Elevated Clinical Disease Activity Scores
Stephanie Song¹, Odette Kolenky¹, Antje Greenfield², Dana Direnzo³, Joshua Baker⁴ and Michael George⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania Health System, Philadelphia, PA, ³University of Pennsylvania, Bala Cynwyd, PA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Treat-to-target is recommended in RA, but physicians often do not escalate therapy despite elevated disease activity measures due to uncertainty regarding the true degree…
Abstract Number: 1630 • ACR Convergence 2023
Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis
Diyu Fisher¹, Dana Orange², Melanie Smith³, Bella Mehta⁴, Edoardo Spolaore⁵, Edward DiCarlo³, Dongmei Sun³, Laura Donlin³ and Susan Goodman³, ¹Stony Brook Medicine, Port Jefferson Station, NY, ²The Rockefeller University, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵HSS, New York, NY
Background/Purpose: Fatigue or tiredness is an important symptom for patients with rheumatoid arthritis (RA), yet the factors associated with fatigue are poorly understood and may…
Abstract Number: 1725 • ACR Convergence 2023
Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model
Yue Peng¹, H. Mark Kenney², Karen Bentley³, Lianping Xing⁴, Christopher T Ritchlin⁵ and Edward Schwarz³, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester School of Medicine and Dentistry, Henrietta, NY, ³University of Rochester, Rochester, NY, ⁴University of Rochester Medical Center, Webster, NY, ⁵University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY
Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1), and mast cells (MCs) regulate lymphatic vessel contractions via release of inflammatory and vasoactive mediators (2).…
Abstract Number: 1742 • ACR Convergence 2023
Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA
Rachna Talluri¹, Sudeshna Sen², Timothy Wilson³, Adam Savage⁴, Mark Gillespie⁴, Tom Bumol⁴, Marie Feser¹, Jill Norri⁵, Michael Holer¹, kevin Deane¹, Paul Thompson² and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Massachusetts Chan Medical School, Worcester, MA, ³Thomas Jefferson University, Philadelphia, PA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Denver, CO
Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
Abstract Number: 1758 • ACR Convergence 2023
Identification of Circulating Autoantibodies Associated with ACPA Status in Early Rheumatoid Arthritis
Lucía Lourido¹, Vijay Joshua², Monika Hansson³, Ronald Sjöberg⁴, Elisa Pin⁴, Cristina Ruiz-Romero⁵, Peter Nilsson⁴, Lars Klareskog² and Francisco J. Blanco⁶, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, Spain, ²Karolinska Institutet, Stockholm, Sweden, ³Division for Rheumatology, Department of Medicine (Solna) Karolinska Institutet, Stockholm, Sweden, ⁴Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, ⁵1) Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España. 4) Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11,28029, Madrid, Spain, ⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with the presence of autoantibodies being the anti-citrullinated protein antibodies (ACPAs) the hallmark as they are present in almost…
Abstract Number: 1774 • ACR Convergence 2023
Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease
José Lisbona-Montañez¹, Patricia Ruiz-Limon², Arkaitz Mucientes³, Natalia Mena Vazquez⁴, Isabel Moreno-Indias³, SARA MANRIQUE⁵, Laura Cano-García⁶, Rocío Redondo-Rodríguez⁶, Francisco J tinahones³ and Antonio Fernandez-Nebro⁷, ¹Universidad de Málaga, Departamento de Medicina y Dermatología, Moclinejo, Spain, ²IBIMA Plataforma BIONAND, Cordoba, Spain, ³IBIMA Plataforma BIONAND, Málaga, Spain, ⁴IBIMA, Málaga, Spain, ⁵Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁶Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁷Hospital Regional Universitario de Málaga, Malaga, Spain
Background/Purpose: Gut microbiota has been related to rheumatoid arthritis (RA), inflammation, and it's severity. Interstitial lung disease (ILD) is the most frequent non-pleural pulmonary manifestation…
Abstract Number: 1896 • ACR Convergence 2023
Systematic Review and Analysis of Mobile Apps for Rheumatoid Arthritis Using the Mobile Application Rating Scale
Pamela Gonzalez Manrique¹, Vinit Gilvaz², Ravinder Kaler³, Neha Batra³ and Anthony Reginato², ¹Roger Williams Medical Center, North Providence, RI, ²The Warren Alpert Medical School of Brown University, Providence, RI, ³Roger Williams Medical Center, Providence, RI
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by inflammatory polyarthritis with infrequent extra-articular involvement. The management of RA typically requires frequent clinic…
Abstract Number: 2095 • ACR Convergence 2023
Integrated Analysis of Gene Expression and Methylation Identifies Biomarkers Associated with Mode of Action of Upadacitinib Treatment in Rheumatoid Arthritis
Preeti Lal¹, Yilin Xu¹, Thierry Sornasse¹, Rhiya Sharma¹, Laleh Jafarpour¹, Heidi Camp¹ and Iain McInnes², ¹AbbVie, Inc., North Chicago, IL, ²University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, significantly improves the signs and symptoms of RA patients1-3. The present study aims to elucidate the…
Abstract Number: 2112 • ACR Convergence 2023
Physical Activity in a Cohort of Patients with Rheumatoid Arthritis
Patricia Dominguez Leiva¹, Joan Manuel Dapeña¹, Juan Manuel Bande¹, Maria Alejandra Medina¹, José caracciolo¹, Diana Klajn¹, Julieta Morbiducci², Anastasia Secco³, Julia Sosa⁴, María Paula Kohan⁴, Dora Pereira⁵ and Silvia Papasidero¹, ¹Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Hospital General de Agudos Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ³Hospital General de Agudos Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, CABA, Argentina, ⁴Hospital Raúl F. Larcade, Provincia de Buenos Aires, Buenos Aires, Argentina, ⁵Instituto Raquis, La Plata, Argentina
Background/Purpose: Physical activity has numerous benefits for Rheumatoid Arthritis (RA) patients such as reducing symptoms like fatigue and pain and improving physical function. The International…
Abstract Number: 2128 • ACR Convergence 2023
Higher Vitamin D Levels Before Methotrexate Start Are Associated with Lower Subsequent Mortality in Rheumatoid Arthritis
Shahdi Malakooti¹, Hinnah Siddiqui², Brigid Wilson², Taissa Bej², Megan O'Mara², Nora Singer³, Grace McComsey⁴, Lenche Kostadinova⁵, Maya Mattar⁶, David Zidar⁵ and Donald Anthony⁷, ¹Case Western Reserve University, Cleveland, OH, ²Louis Stokes Cleveland VA Medical Center, Cleveland, OH, ³The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁴University Hospitals Health System at Case Western Reserve University, Cleveland, OH, ⁵Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, OH, ⁶Louis Stokes VA Medical Center, Cleveland, OH, ⁷Case Western Reserve University, Cleveland VA Medical Center, The MetroHealth System, Cleveland, OH
Background/Purpose: Vitamin D is an immune-modulating hormone. Low Vitamin D levels have been associated with development of autoimmune disease and higher disease activity in early…
Abstract Number: 2144 • ACR Convergence 2023
Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study
Rohit Panchakshari¹, Matthew Loza², Thomas Huizinga³, Georg Schett⁴, Keying Ma², Jocelyn H. Leu², Sophia G. Liva², Fowzia Ibrahim⁵, Bei Zhou⁶, Qingmin Wang², Ricardo Rojo Cella², Chetan S. Karyekar², Kaiyin Fei², Carolyn Cuff⁷ and Sheng Gao², ¹Janssen Research & Development, LLC, La Jolla, CA, ²Janssen Research & Development, LLC, Spring House, PA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁵Janssen Research & Development, LLC, High Wycombe, United Kingdom, ⁶Janssen Research & Development, LLC, Chesterbrook, PA, ⁷Janssen Research & Development, LLC, Cambridge, MA
Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that blocks the neonatal crystallizable fragment receptor (FcRn), thereby lowering IgG levels. RA…
Abstract Number: 2160 • ACR Convergence 2023
Poly-Refractory Rheumatoid Arthritis: All B/tsDMARD Classes Exhausted – An Uncommon Disease Subset with Distinct Inflammatory and Non-inflammatory Phenotypes
Paula David¹, Andrea Di Matteo¹, Or Hen¹, Shouvik Dass², Helena Marzo-Ortega³, Paul Emery⁴, Benazir Saleem² and Dennis McGonagle⁵, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ³NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: We previously reported on difficult to treat Rheumatoid Arthritis (RA) in nearly 1600 patients treated with biologic (b) or target synthetic (ts) DMARDs including…
Abstract Number: 2426 • ACR Convergence 2023
The Role of β-catenin in Synovial Lining Fibroblast Differentiation
Sonia Presti¹, Gerald F.M. Watts¹, Junning Case¹, Zhu Zhu², Teri Bowman¹, Hung Nguyen¹, Gabriel Nigrovic¹, Ce Gao¹, Kartik Bhamidipati¹, Yuhong Li¹, Suppawat Kongthong¹, Fan Zhang³, Anna Helena Jonsson¹, Accelerating Medicines Partnership Program (AMP RA/SLE) Network⁴, STARS BWH¹, Michael Brenner⁵, Shideh Kazerounian¹ and Kevin Wei⁵, ¹Brigham and Women's Hospital, Boston, MA, ²10x Genomics, St. Louis, MO, ³University of Colorado, Aurora, CO, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In healthy synovium, lining fibroblasts promote joint health by secreting proteoglycans that lubricate the joint cavity. In rheumatoid arthritis (RA), sublining fibroblasts undergo marked…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].